<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613284</url>
  </required_header>
  <id_info>
    <org_study_id>CXW001</org_study_id>
    <nct_id>NCT04613284</nct_id>
  </id_info>
  <brief_title>Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>Rh-Endostatin Combined With Low-dose CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC Who Can Not Tolerate 60 Gy Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Assess the Effects of Durvalumab following Rh-Endostatin combined with&#xD;
      reduced-dose CCRT(50 Gy) in Patients with Stage III Unresectable Non-Small Cell Lung Cancer&#xD;
      who can not tolerate 60 Gy irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, Single-arm, Multi-centre Study of Durvalumab as Sequential Therapy in Patients&#xD;
      with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not&#xD;
      Progressed Following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) Therapy (Relief)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>PFS was defined as the time from randomization until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events (AE)</measure>
    <time_frame>5 years from patient enrollment</time_frame>
    <description>Number of participants with adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years from patient enrollment</time_frame>
    <description>OS was defined as the time from the date of randomization until death due to any cause. OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~ 12 weeks thereafter up to 3 three years</time_frame>
    <description>ORR was defined as the percentage of patients with at least one visit response of Complete Response (CR) or Partial Response (PR) per RECIST 1.1 for target lesions: CR: Disappearance of all target lesions; PR: &gt;=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endostar combined Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human endostatin (Endostar)</intervention_name>
    <description>Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.</description>
    <arm_group_label>Endostar combined Radiation</arm_group_label>
    <other_name>Durvalumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic irradiation of 50 Gy with 3DCRT or IMRT</intervention_name>
    <description>Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.</description>
    <arm_group_label>Endostar combined Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at 18-75 years.&#xD;
&#xD;
          -  Documented evidence of NSCLC (locally advanced, unresectable, Stage III)&#xD;
&#xD;
          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1.&#xD;
&#xD;
          -  Estimated life expectancy of more than 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.&#xD;
&#xD;
          -  Active or prior autoimmune disease or history of immunodeficiency.&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases, including active bleeding&#xD;
             diatheses or active infections including hepatitis B, C and HIV.&#xD;
&#xD;
          -  Evidence of uncontrolled illness such as symptomatic congestive heart failure,&#xD;
             uncontrolled hypertension or unstable angina pectoris.&#xD;
&#xD;
          -  Any unresolved toxicity CTCAE &gt;Grade 2 from the prior chemoradiation therapy.&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xuwei Cai</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

